Ken-Ichi Inui
Overview
Explore the profile of Ken-Ichi Inui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
4159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexander S, Fabbro D, Kelly E, Mathie A, Peters J, Veale E, et al.
Br J Pharmacol
. 2023 Dec;
180 Suppl 2:S374-S469.
PMID: 38123156
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of...
2.
Nies A, Konig J, Leuthold P, Damme K, Winter S, Haag M, et al.
Pharmacol Res
. 2023 Sep;
196:106941.
PMID: 37775020
Solute carrier (SLC) transport proteins are fundamental for the translocation of endogenous compounds and drugs across membranes, thus playing a critical role in disease susceptibility and drug response. Because only...
3.
Alexander S, Kelly E, Mathie A, Peters J, Veale E, Armstrong J, et al.
Br J Pharmacol
. 2021 Sep;
178 Suppl 1:S412-S513.
PMID: 34529826
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of...
4.
Tanihara Y, Masuda S, Inui K
Eur J Pharm Sci
. 2020 Dec;
158:105666.
PMID: 33296710
Vandetanib (ZD6474, Zactima®, Caprelsa®) is a newly developed dual tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor. Recently, several reports have indicated the interaction of...
5.
Ichida A, Motohashi H, Kitano A, Takayama A, Inui K, Yano Y
Ther Innov Regul Sci
. 2018 Sep;
50(3):355-360.
PMID: 30227075
Background: Telaprevir is a protease inhibitor currently used in the treatment of chronic hepatitis C virus (HCV) infection. One of its adverse effects is renal impairment. The Pharmaceutical and Medical...
6.
Kitano A, Motohashi H, Takayama A, Inui K, Yano Y
Ther Innov Regul Sci
. 2018 Sep;
49(1):81-85.
PMID: 30222448
Background: More than 250,000 reports of adverse drug events were included in the database of the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. However, these data have not been...
7.
Zhou Z, Yano I, Odaka S, Morita Y, Shizuta S, Hayano M, et al.
J Pharm Health Care Sci
. 2016 Aug;
2:17.
PMID: 27493787
Background: Catheter ablation is a non-medication therapy for atrial fibrillation, and during the procedure, warfarin is withdrawn in the preoperative period to prevent the risk of bleeding. In case of...
8.
Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, et al.
Sci Rep
. 2016 Jun;
6:27557.
PMID: 27272163
Homeostasis of riboflavin should be maintained by transporters. Previous in vitro studies have elucidated basic information about riboflavin transporter RFVT3 encoded by SLC52A3 gene. However, the contribution of RFVT3 to...
9.
Terada T, Noda S, Inui K
Pharmacol Ther
. 2015 May;
152:125-34.
PMID: 25976912
Molecular-targeted therapies with tyrosine kinase inhibitors (TKIs) have provided a major breakthrough in cancer treatment. These agents are given orally and demonstrated to be substrates for drug transporters. In clinical...
10.
Nakano K, Ando H, Kurokawa S, Hosohata K, Ushijima K, Takada M, et al.
Cancer Chemother Pharmacol
. 2015 Apr;
75(6):1191-7.
PMID: 25862351
Purpose: The anti-prostate cancer drug flutamide occasionally causes hepatotoxicity, and predictive biomarkers of flutamide-induced liver injury (FILI) are needed to improve safety of this drug. The aim of this prospective...